NO122591B - - Google Patents
Download PDFInfo
- Publication number
- NO122591B NO122591B NO14416162A NO14416162A NO122591B NO 122591 B NO122591 B NO 122591B NO 14416162 A NO14416162 A NO 14416162A NO 14416162 A NO14416162 A NO 14416162A NO 122591 B NO122591 B NO 122591B
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- pregnadiene
- water
- halogen
- denotes
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 15
- -1 acyl radical Chemical class 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 150000005840 aryl radicals Chemical class 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000012279 sodium borohydride Substances 0.000 claims 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000002198 insoluble material Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
- 229940067157 phenylhydrazine Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- XKLVLDXNZDIDKQ-UHFFFAOYSA-N butylhydrazine Chemical class CCCCNN XKLVLDXNZDIDKQ-UHFFFAOYSA-N 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical group CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Description
Fremgangsmåte til fremstilling av nye 17a, 21-dihydroxy-20-oxo-4,6-pregnadien- [3,2-c]-pyrazol-forbindelser eller deres 21-estere med antiflammatorisk virkning. Process for the production of new 17a, 21-dihydroxy-20-oxo-4,6-pregnadiene-[3,2-c]-pyrazole compounds or their 21-esters with anti-inflammatory action.
Foreliggende oppfinnelse angår en fremgangsmåte til fremstilling av nye 17a,21-dihydroxy-20-oxo-4,6-pregnadien-[ 3,2-c]-pyra-zol-forbindelser eller deres 21-estere. The present invention relates to a method for the production of new 17a,21-dihydroxy-20-oxo-4,6-pregnadiene-[3,2-c]-pyrazole compounds or their 21-esters.
Disse forbindelser tilsvarer én av de nedenstående generel- ■ le formler: These compounds correspond to one of the general formulas below:
i hvilke R^betegner p-halogen, en p-hydroxy eller keto-gruppe, og X betegner hydrogen eller halogen, idet R^kari være p-halogen bare i de tilfelle hvor1 også X er halogen, R_ betegner hydrogen, fluor eller en raethylgruppe, R^ betegner en a-methyl-, p-methyl- eller en methylen-gruppe, R4 betegner hydrogen eller et acylradikal eller et fosforsyre-radikal og R5betegner et alkyl-, cycloalkyl-, aralkyl- eller arylradikal. in which R^ denotes p-halogen, a p-hydroxy or keto group, and X denotes hydrogen or halogen, R^ can be p-halogen only in those cases where X is also halogen, R_ denotes hydrogen, fluorine or a raethyl group, R 1 denotes an α-methyl, p-methyl or a methylene group, R 4 denotes hydrogen or an acyl radical or a phosphoric acid radical and R 5 denotes an alkyl, cycloalkyl, aralkyl or aryl radical.
Det karakteristiske hovedtrekk ved oppfinnelsen er at man omsetter en 17a,21-dihydroxy-3,20-dioxo-2-hydroxymethylen- eller 2-alkoxymethylen-4,6-pregnadien-forbindelse tilsvarende en av de ovenfor angitte forbindelser, og i hvilken beskyttende grupper kan være tilstede i 17-, 20- og 21-stillingene, med et hydrazin med formelen R5-NHNH2, hvor R,, har den ovenfor angitte betydning, hvorpå man fjer-ner eventuelt tilstedeværende beskyttende grupper i 17-, 20- og 21- stillingene, og, om onskes, overforer det erholdte produkt til et 21-organisk acylat eller til et 21-fosfat. The characteristic main feature of the invention is that one reacts a 17a,21-dihydroxy-3,20-dioxo-2-hydroxymethylene- or 2-alkoxymethylene-4,6-pregnadiene compound corresponding to one of the above-mentioned compounds, and in which protective groups can be present in the 17-, 20- and 21-positions, with a hydrazine of the formula R5-NHNH2, where R,, has the above meaning, after which any protective groups present in the 17-, 20- and the 21-positions, and, if desired, transfers the product obtained to a 21-organic acylate or to a 21-phosphate.
De forbindelser som fåes ved fremgangsmåten ifolge oppfinnelsen, har en sterk anti-inflammatorisk virkning og er særlig effektive til behandling av arthrit og beslektede sykdommer, da de har cortison-lignende virkning i så sterk grad at de kan anvendes i relativt små doser, hvorved uonskede bivirkninger blir ubetydelige. The compounds obtained by the method according to the invention have a strong anti-inflammatory effect and are particularly effective for the treatment of arthritis and related diseases, as they have a cortisone-like effect to such a strong extent that they can be used in relatively small doses, whereby unwanted side effects become negligible.
Utgangsmaterialene for fremgangsmåten ifolge oppfinnels en kan fremstilles fra et 17a,21-dihydroxy-4,6-pregnadien-3,20-dion med den generelle formel: The starting materials for the method according to the invention can be prepared from a 17a,21-dihydroxy-4,6-pregnadiene-3,20-dione with the general formula:
i hvilken R^, R,,, R^og X har den ovenfor angitte betydning og be-grensning av betydningen av R^. Således kan f.eks. kold, konsentrert saltsyre og formalin tilsettes til en omrort suspensjon i kloroform, med temperatur ca. 0°C, av den ovenfor angitte forbindelse. Man lar derpå blandingens temperatur stige til romtemperatur og omrorer den i flere timer, hvorved der dannes det tilsvarende 17a,20,20,21-bis-(methylendioxy)-derivat. in which R^, R^,, R^ and X have the above stated meaning and limitation of the meaning of R^. Thus, e.g. cold, concentrated hydrochloric acid and formalin are added to a stirred suspension in chloroform, at a temperature of approx. 0°C, of the above compound. The temperature of the mixture is then allowed to rise to room temperature and it is stirred for several hours, whereby the corresponding 17a,20,20,21-bis-(methylenedioxy)-derivative is formed.
Ved behandling av en lip-hydroxy-, lip-halogen- ellar 11-keto-17a,20,20,21-bis(methylendioxy)-4,6-pregnadien-3-on-fprbindelse med et alkylformiat og natriumhydrid i inert atmosfære dannes det tilsvarende 17a,20,20,21-bis(methylendioxy)-2-hydrpxymethylen-4,6-pregnadien-3-on med den generelle formel: On treatment of a lip-hydroxy-, lip-halo- or 11-keto-17a,20,20,21-bis(methylenedioxy)-4,6-pregnadien-3-one compound with an alkyl formate and sodium hydride in an inert atmosphere the corresponding 17a,20,20,21-bis(methylenedioxy)-2-hydrpxymethylene-4,6-pregnadien-3-one is formed with the general formula:
i hvilken R^, R^> Rg°9x nar de foran angitte betydninger, inklusi-ve begrensningen at R^kan være p-halogen bare i de tilfelle at også in which R^, R^> Rg°9x have the previously stated meanings, including the restriction that R^ can be p-halogen only in the case that also
X er halogen. X is halogen.
Således kan steroid opploses i et opplosningsmiddel som benzen, og den erholdte opplosning avkjoles til romtemperatur med på-i Thus, steroid can be dissolved in a solvent such as benzene, and the resulting solution is cooled to room temperature with on-i
folgende behandling med ethylformiat. Luften i reaksjonssonen erstat-tes hensiktsmessig med nitrogen, natriumhydrid tilsettes, hvorpå blandingen omrores ved romtemperatur i flere timer. following treatment with ethyl formate. The air in the reaction zone is suitably replaced with nitrogen, sodium hydride is added, after which the mixture is stirred at room temperature for several hours.
Ved behandling av en 17a,20,20,21-bis(methylendioxy)-2-hydroxymethylen-4,6-pregnadien-3-on-forbind else med en lavere alkanol i nærvær av et surt stoff som p-toluensulfonsyre, dannes det tilsvarende 17a,20,20,21-bis(methylendioxy)-2-alkoxymethylen-4,6-pregnadien-3-on. On treatment of a 17a,20,20,21-bis(methylenedioxy)-2-hydroxymethylene-4,6-pregnadien-3-one compound with a lower alkanol in the presence of an acidic substance such as p-toluenesulfonic acid, it is formed corresponding to 17a,20,20,21-bis(methylenedioxy)-2-alkoxymethylene-4,6-pregnadien-3-one.
Sorn det fremgår av det foran angitte omsetter man, ifolge oppfinnelsen, dette utgångsmateriale med et hydrazin som inneholder substituenten R^_. As can be seen from the foregoing, according to the invention, this starting material is reacted with a hydrazine containing the substituent R^_.
De N-substituerte-4,6-pregnadien-[3,2-c]-pyrazoler som tilsvarer nedenstående generelle formel A kan betegnes som 1'-substituerte 4,6-pregnadien-[3,2-c]-pyrazoler, mens de N-substituerte pyra-zol-forbindelser tilsvarende nedenstående generelle formel B kan betegnes som 2'-substituerte 4,6-pregnadien-[3,2-c]-pyrazoler. The N-substituted-4,6-pregnadiene-[3,2-c]-pyrazoles corresponding to the general formula A below can be designated as 1'-substituted 4,6-pregnadiene-[3,2-c]-pyrazoles, while the N-substituted pyrazole compounds corresponding to the general formula B below can be designated as 2'-substituted 4,6-pregnadiene-[3,2-c]-pyrazoles.
I disse generelle formler har R^, R^, R^, R^og X de ovenfor angitte betydninger. In these general formulas R^, R^, R^, R^ and X have the meanings given above.
Ved behandling av en 17a,20,20,21-bis-(methylendioxy)-2-hydroxymethylen-4,6-pregnadien-3-on-forbindelse direkte med et monosubstituert arylhydrazin, uten dannelse av 2-alkoxymethylenderivatet som mellomprodukt, dannes i alminnelighet den ene isomer i overveien-de mengde. Når man derimot omsetter en 17a,20,20,21-bis(methylendi-oxy)-2-alkoxymethylen-4,6-pregnadien-3-on-forbindelse med et monosubstituert arylhydrazin, får man betydelige mengder av begge isomere. Når man utforer disse reaksjoner med monosubstituerte alkylhydraziner får man blandinger uansett om man går ut fra 2-hydroxymethylensteroi-det eller fra 2-alkoxymethylensteroidet. En blanding av de isomere kan også dannes ved omsetning av et monosubstituert hydrazin med en 2-hydroxymethylen-forbindelse som eventuelt inneholder varierende mengder av 2-alkoxymethylenderivatet, i avhengighet av de anvendte arbeidsbetingelser, f.eks. på grunn av omkrystallisasjon i nærvær av et spor av alkohol av en opplosning av 2-hydroxymethylen-forbindel-sen, fra hvilken syre ikke er fjernet fullstendig. On treatment of a 17a,20,20,21-bis-(methylenedioxy)-2-hydroxymethylene-4,6-pregnadien-3-one compound directly with a monosubstituted arylhydrazine, without formation of the 2-alkoxymethylene derivative as an intermediate, is formed in usually the one isomer in the predominating amount. On the other hand, when one reacts a 17a,20,20,21-bis(methylenedi-oxy)-2-alkoxymethylene-4,6-pregnadien-3-one compound with a monosubstituted arylhydrazine, significant amounts of both isomers are obtained. When these reactions are carried out with monosubstituted alkylhydrazines, mixtures are obtained, regardless of whether one starts from the 2-hydroxymethylene steroid or from the 2-hydroxymethylene steroid. A mixture of the isomers can also be formed by reacting a monosubstituted hydrazine with a 2-hydroxymethylene compound which optionally contains varying amounts of the 2-alkoxymethylene derivative, depending on the working conditions used, e.g. due to recrystallization in the presence of a trace of alcohol of a solution of the 2-hydroxymethylene compound from which acid has not been completely removed.
Blant de monosubstituerte hydraziner som kan anvendes i fremgangsmåten ifolgeOppfinnelsen er alkylhydraziner, som methylhyd-razin, ethylhydrazin, propyohydraziner og butylhydraziner, cycloalkyl-hydraziner, arylhydraziner deriblant fenylhydraziner som kan være substituert med et halojenatom samt aralkylhydraziner, som benzylhyd-razin og fenylethylenhydrazin. Among the monosubstituted hydrazines that can be used in the method according to the invention are alkylhydrazines, such as methylhydrazine, ethylhydrazine, propiohydrazines and butylhydrazines, cycloalkylhydrazines, arylhydrazines including phenylhydrazines which may be substituted with a halogen atom and aralkylhydrazines, such as benzylhydrazine and phenylethylenehydrazine.
Ved behandling av hvilken som helst av de ovenfor beskrev-ne 17a,20,20,21-bis(methylendioxy)-4,6-pregnadien-[3,2-c]-pyrazol-forbindelser med en fortynnet organisk syre, f.eks. en 60 %'s vandig maursyre, fjernes den gruppe som beskytter 17a,20,20,21-bis(methylen-dioxy), og man får den tilsvarende 17a,21-dihydroxy-20-oxo-4,6-pregna-dien- [3,2-c]-pyrazol. When treating any of the above-described 17a,20,20,21-bis(methylenedioxy)-4,6-pregnadiene-[3,2-c]-pyrazole compounds with a dilute organic acid, e.g. e.g. a 60% aqueous formic acid, the group protecting 17a,20,20,21-bis(methylenedioxy) is removed, and the corresponding 17a,21-dihydroxy-20-oxo-4,6-pregna-diene is obtained - [3,2-c]-pyrazole.
21-acylat-derivatene av de ovenfor angitte 17a,21-dihydroxy-20-oxo-4,6-pregnadien-[3,2-c]-pyrazoler kan fremstilles ved omsetning av disse med et acyleringsmiddel. Egnede acyleringsmidler for dette formål er hydrocarboncarboxylsyrer eller derivater av sådanne som benzoesyreanhydrid, tertiært butyl-acetylklorid, alkansyreanhydrider eller -halogenider, som eddiksyreanhydrid, propionsyreanhydrid, eller anhydrider av flerbasiske syrer som B,B-dimethyl-glutarsyreanhydrid, ravsyreanhydrid og lignende. Man arbeider herved i nærvær av en organisk base som pyridin. The 21-acylate derivatives of the above-mentioned 17a,21-dihydroxy-20-oxo-4,6-pregnadiene-[3,2-c]-pyrazoles can be prepared by reacting these with an acylating agent. Suitable acylating agents for this purpose are hydrocarbon carboxylic acids or derivatives thereof such as benzoic anhydride, tertiary butyl acetyl chloride, alkanoic anhydrides or halides, such as acetic anhydride, propionic anhydride, or anhydrides of polybasic acids such as B,B-dimethyl-glutaric anhydride, succinic anhydride and the like. This is done in the presence of an organic base such as pyridine.
I det fblgende beskrives som eksempler noen utforelsesfor-mer for oppfinnelsen. In the following, some embodiments of the invention are described as examples.
Eksempel 1 Example 1
1,19 g 17a,20,20,21-bis-(methylendioxy)-llB-hydroxy-2-hydroxymethylen-6,16a-dimethyl-4,6-pregnadien-3-on opploses i 25 ml ethanol. Oppløsningen tilsettes 300 mg fenylhydrazin, og blandingen oppvarmes i nitrogenatmosfære under tilbakelopskjoling i 1 time, hvorpå den tilsettes 25 ml vann. Produktet ekstraheres med 150 ml ether. Ekstraktene vaskes med 2 N saltsyre, med mettet natriumbicarbonatopplosning, med vann og med mettet natriumkloridopplosning. De befries derpå for vann med natriumsulfat og inndampes til torrhet, hvorved man får ca. 1,2 g råprodukt. Dette omkrystalliseres fra ether, hvorved man får ét stoff hvis hovedbestanddel er 17a,20,20,21-bis-(methy-len )-llS-hydrqxy-6,16a-dimethyl-ll-oxo-2*-fenyl-4,6-pregnadien- 1.19 g of 17a,20,20,21-bis-(methylenedioxy)-11B-hydroxy-2-hydroxymethylene-6,16a-dimethyl-4,6-pregnadien-3-one is dissolved in 25 ml of ethanol. 300 mg of phenylhydrazine is added to the solution, and the mixture is heated in a nitrogen atmosphere under reflux for 1 hour, after which 25 ml of water is added. The product is extracted with 150 ml of ether. The extracts are washed with 2 N hydrochloric acid, with saturated sodium bicarbonate solution, with water and with saturated sodium chloride solution. They are then freed from water with sodium sulphate and evaporated to dryness, whereby approx. 1.2 g raw product. This is recrystallized from ether, whereby one substance is obtained whose main constituent is 17a,20,20,21-bis-(methylene)-11S-hydroxy-6,16a-dimethyl-11-oxo-2*-phenyl-4, 6-pregnadien-
[3,2-c]-pyrazol, med sm.p. 258 - 262°C. a^<4>= -123(CHC13) [3,2-c]-pyrazole, with m.p. 258 - 262°C. a^<4>= -123(CHC13)
UltrafiolettÅ^^g = 283.315 mp.. £=17200, 20800. UltravioletÅ^^g = 283.315 mp.. £=17200, 20800.
17a,20,20,21-bis-(methylendioxy)-llB-hydroxy-6,16-dimeth-yl-2'-fenyl-4,6-pregnadien-[3,2-c]-pyrazolet (430 mg) oppvarmes på dampbad i nitrogenatmosfære med 40 ml 60 %'s vandig maursyre i ca. 30 minutter. Derefter tilsettes ca. 40 ml vann, og blandingen ekstraheres med 2O0 ml kloroform. Kloroformekstraktet vaskes med vann, med mettet natriumbicarbonatopplosning og påny med,vann, hvorpå den befries for vann med na triumsulfat og inndampes i vakuum, hvorved man får ca. 430 mg urent produkt. Dette opploses i 60 ml absolutt methanol, og oppløsningen tilsettes O,1 ekvivalent natrium-methylat i methanol. Blandingen omrbres i nitrogenatmosfære ved romtemperatur i 15 minutter. Den surgjdres derpå med eddiksyre, og opplosningsmidlet fjernes i vakuum ved romtemperatur. Der tilsettes ca. 20 ml vann, og produktet ekstraheres med 150 ml ethylacetat. Ethylacetatekstraktet vaskes med mettet natriumbicarbonatopplosning og derpå med vann. Det befries for vann med natriumsulfat og inndampes til torrhet, hvorved man får et amorft stoff. 17a,20,20,21-bis-(methylenedioxy)-11B-hydroxy-6,16-dimeth-yl-2'-phenyl-4,6-pregnadiene-[3,2-c]-pyrazole (430 mg) heated on a steam bath in a nitrogen atmosphere with 40 ml of 60% aqueous formic acid for approx. 30 minutes. Then add approx. 40 ml of water, and the mixture is extracted with 200 ml of chloroform. The chloroform extract is washed with water, with saturated sodium bicarbonate solution and again with water, after which it is freed from water with sodium sulphate and evaporated in a vacuum, whereby approx. 430 mg impure product. This is dissolved in 60 ml of absolute methanol, and 0.1 equivalent of sodium methylate in methanol is added to the solution. The mixture is stirred in a nitrogen atmosphere at room temperature for 15 minutes. It is then acidified with acetic acid, and the solvent is removed in vacuo at room temperature. Add approx. 20 ml of water, and the product is extracted with 150 ml of ethyl acetate. The ethyl acetate extract is washed with saturated sodium bicarbonate solution and then with water. It is freed from water with sodium sulphate and evaporated to dryness, whereby an amorphous substance is obtained.
Dette urene produkt torres i hoyt vakuum og opploses i 4 ml pyridin. Oppløsningen tilsettes ca. 3 ml eddiksyreanhydrid. Blandingen oppvarmes derpå på dampbad i ca. 15 minutter og inndampes til torrhet i vakuum. Residuet tilsettes ca. 20 ml vann. Produktet ekstraheres med 150 ml ethylacetat, ekstraktet vaskes med mettet natriumbicarbonatopplosning og med vann, hvorpå det befries for vann med nat-riumsulf at.. Opplosningsmidlet fjernes i vakuum, hvorved man får et residuum som omkrystalliseres fra en blanding av ethylacetat og benzen. Man får ca. 250 mg 116,17a,21-trihydroxy-6,16a-dimethyl-20-oxo-2'-fen-yl-4, 6-pregnadien- [3, 2-c]pyrazol-21-acetat med sm.p. (dobbelt) 160 165°C og 229 230°C. a^<3>= + 14°C (CHC13). Ultrafiolett A ^aks This impure product is dried under high vacuum and dissolved in 4 ml of pyridine. The solution is added approx. 3 ml of acetic anhydride. The mixture is then heated in a steam bath for approx. 15 minutes and evaporated to dryness in a vacuum. The residue is added approx. 20 ml of water. The product is extracted with 150 ml of ethyl acetate, the extract is washed with saturated sodium bicarbonate solution and with water, after which it is freed from water with sodium sulphate. The solvent is removed in vacuo, whereby a residue is obtained which is recrystallized from a mixture of ethyl acetate and benzene. You get approx. 250 mg of 116,17a,21-trihydroxy-6,16a-dimethyl-20-oxo-2'-phenyl-4, 6-pregnadiene-[3, 2-c]pyrazole-21-acetate with m.p. (double) 160 165°C and 229 230°C. a^<3>= + 14°C (CHCl 3 ). Ultraviolet A ^aks
283,315 mp. S. = 15,700, 19000. 283.315 mp. S. = 15,700, 19000.
Eksempel 2 Example 2
111,5 mg 17a,20,20,21-bis-(methylendioxy)-llB-hydroxy-2-hydroxymethylen-16a-methyl-4,6-pregnadien-3-on suspenderes i 2,5 ml ethanol, og suspensjonen behandles med 24,5 mg natriumacetat, hvorpå 111.5 mg of 17a,20,20,21-bis-(methylenedioxy)-11B-hydroxy-2-hydroxymethylene-16a-methyl-4,6-pregnadien-3-one are suspended in 2.5 ml of ethanol, and the suspension is treated with 24.5 mg of sodium acetate, whereupon
den tilsettes 48,5 mg p-fluorfenylhydrazinhydroklorid. Luften i reaksjonssonen fortrenges med nitrogen, og blandingen bringes raskt på ko-ketemperatur. Efter kokning under tilbakelbpskjbling i 1 time inndampes blandingen til torrhet. Residuet opploses i ether, etherskiktet 48.5 mg of p-fluorophenylhydrazine hydrochloride is added to it. The air in the reaction zone is displaced with nitrogen, and the mixture is quickly brought to boiling temperature. After boiling under reflux for 1 hour, the mixture is evaporated to dryness. The residue is dissolved in ether, the ether layer
behandles tre ganger med 2,5 N saltsyre og derpå tre ganger med 2,5 treated three times with 2.5 N hydrochloric acid and then three times with 2.5
N natriumhydroxydopplosning samt sluttelig med vann. Etherskiktet befries for vann med magnesiumsulfat, filtreres og inndampes til torrhet i vakuum, hvorved man får et residuum hvis hovedbestanddel er 17a,20,20,21-bis-(methylendioxy)-2'-p-fluorfenyl-llB-hydroxy-16a-methyl-4,6-pregnadien-[3,2-c]pyrazol. Denne forbindelse kan isoler-es ved å opplose reaksjonsblandingen i methanol og omkrystallisere. N sodium hydroxide solution and finally with water. The ether layer is freed from water with magnesium sulfate, filtered and evaporated to dryness in vacuo, whereby a residue is obtained whose main constituent is 17a,20,20,21-bis-(methylenedioxy)-2'-p-fluorophenyl-11B-hydroxy-16a- methyl-4,6-pregnadiene-[3,2-c]pyrazole. This compound can be isolated by dissolving the reaction mixture in methanol and recrystallizing.
70 mg 17a,20,20,21-bis-(methylendioxy)-16a-methyl-2'-(p-fluorfenyl)-lip-hydroxy-4,6-pregnadien-[3,2-c]pyrazol oppvarmes på dampbad med 2 ml 60 %'s vandig maursyre i 35 minutter. Overskuddet av reagens fjernes i vakuum på vannbad med temperatur ca. 50°C. Residuet vaskes grundig med vann og torres ved 80°C. Residuet vaskes grundig med vann og torres ved 80°C, hvorved man får 61,1 eng residuum. Dette residuum opploses i 3 ml spektrografisk ren methanol hvorpå det omsettes med 0,5 ml av en 0,1 N opplosning av natrium-methylat i methanol ved romtemperatur i 10 minutter. Produktet nbytraliseres med eddiksyre. Blandingen inndampes derpå til torrhet og vaskes grundig med vann, filtreres og torres til konstant vekt, hvorved man får lip,17a,21-trihydroxy-2'-(p-fluorfenyl)-16a-methyl-20-oxo-4,6-pregna-dien- [3,2-c]pyrazol, med sm.p. 197 - 203°C. a^5 = -26° (aceton) 70 mg of 17a,20,20,21-bis-(methylenedioxy)-16a-methyl-2'-(p-fluorophenyl)-lip-hydroxy-4,6-pregnadiene-[3,2-c]pyrazole is heated on a steam bath with 2 ml of 60% aqueous formic acid for 35 minutes. The excess reagent is removed in a vacuum in a water bath with a temperature of approx. 50°C. The residue is washed thoroughly with water and dried at 80°C. The residue is washed thoroughly with water and dried at 80°C, whereby 61.1 eng of residue is obtained. This residue is dissolved in 3 ml of spectrographically pure methanol, after which it is reacted with 0.5 ml of a 0.1 N solution of sodium methylate in methanol at room temperature for 10 minutes. The product is neutralized with acetic acid. The mixture is then evaporated to dryness and washed thoroughly with water, filtered and dried to constant weight, whereby lip,17a,21-trihydroxy-2'-(p-fluorophenyl)-16a-methyl-20-oxo-4,6- pregna-diene-[3,2-c]pyrazole, with m.p. 197 - 203°C. a^5 = -26° (acetone)
Ultrafiolett A = 280,313 m\ i. 15800, 19300. Ultraviolet A = 280.313 m\ in. 15800, 19300.
Eksempel 3 Example 3
En blanding av 71,6 mg 17a,20,20,21-bis-(methylendioxy)-9a-fluor-2-hydroxymethylen-16a-methyl-4,6-pregnadien-3,11-dion og 0,02 ml fenylhydrazin oppvarmes under tilbakelbpskjbling i 0,97 ml absolutt ethanol i 1 time. Et krystallinsk stoff skiller sig ut i varmen. Reaks jonsblandingen avkjbles og filtreres. Produktet vaskes med kold methanol, hvorved man får et stoff hvis hovedbestanddel er 17a,20,20,21-bis-(methylendioxy)-9a-fluor-16a-methyl-ll-oxo-2<1->fenyl-4,6-pregnadieh-[3,2-c]pyrazol. A mixture of 71.6 mg of 17a,20,20,21-bis-(methylenedioxy)-9a-fluoro-2-hydroxymethylene-16a-methyl-4,6-pregnadiene-3,11-dione and 0.02 ml of phenylhydrazine heated under reflux in 0.97 ml of absolute ethanol for 1 hour. A crystalline substance stands out in the heat. The reactive ion mixture is cooled and filtered. The product is washed with cold methanol, whereby a substance is obtained whose main constituent is 17a,20,20,21-bis-(methylenedioxy)-9a-fluoro-16a-methyl-11-oxo-2<1->phenyl-4,6 -pregnadieh-[3,2-c]pyrazole.
29,5 mg av sistnevnte forbindelse oppvarmes i nitrogenatmosfære på dampbad i 1 time samt 5 minutter i nitrogenatmosfære med 12 ml 60 %'s vandig maursyre. Den erholdte opplosning inndampes til torrhet, tilsettes vann og produktet f raf Utreres, hvorved man får 9a-fluor-17a,21-dihydroxy-16a-methyl-ll,20-dioxo-2'-fenyl-4,6-pregna-dien- [3,2-c]pyrazol. 29.5 mg of the latter compound are heated in a nitrogen atmosphere on a steam bath for 1 hour and 5 minutes in a nitrogen atmosphere with 12 ml of 60% aqueous formic acid. The obtained solution is evaporated to dryness, water is added and the product from raf is extracted, whereby 9a-fluoro-17a,21-dihydroxy-16a-methyl-11,20-dioxo-2'-phenyl-4,6-pregna-diene is obtained - [3,2-c]pyrazole.
15 mg 17a,20,20,21-bis-(methylendioxy)-9a-fluor-16a-methyl-ll-oxo-2<1->fenyl-4,6-pregnadien-[3,2-c]pyrazol opploses i methylenklo- 15 mg of 17a,20,20,21-bis-(methylenedioxy)-9a-fluoro-16a-methyl-11-oxo-2<1->phenyl-4,6-pregnadiene-[3,2-c]pyrazole is dissolved in methylene chloride
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10653961A | 1961-05-01 | 1961-05-01 | |
US156478A US3067194A (en) | 1961-12-01 | 1961-12-01 | 4, 6-pregnadieno-[3, 2-c] pyrazoles and processes of preparing them |
Publications (1)
Publication Number | Publication Date |
---|---|
NO122591B true NO122591B (en) | 1971-07-19 |
Family
ID=26803782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO14416162A NO122591B (en) | 1961-05-01 | 1962-04-27 |
Country Status (7)
Country | Link |
---|---|
BE (1) | BE617105A (en) |
CH (1) | CH423768A (en) |
DE (1) | DE1468211B1 (en) |
DK (2) | DK108168C (en) |
ES (1) | ES277085A1 (en) |
NO (1) | NO122591B (en) |
SE (1) | SE309590B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1053502B (en) * | 1956-01-26 | 1959-03-26 | Syntex Sa | Process for the preparation of 2-alkyl and 2-aralkyl derivatives of A4-pregnen-3, 20-dione, A4-pregnen-17alpha-ol-3, 20-dione, A4-pregnen-21-ol-3, 20-dione and A4-Pregnen-17alpha, 21-diol-3, 20-dione |
-
1962
- 1962-04-27 SE SE478562A patent/SE309590B/xx unknown
- 1962-04-27 NO NO14416162A patent/NO122591B/no unknown
- 1962-04-28 ES ES277085A patent/ES277085A1/en not_active Expired
- 1962-04-30 DE DE19621468211 patent/DE1468211B1/en active Pending
- 1962-04-30 BE BE617105A patent/BE617105A/en unknown
- 1962-05-01 CH CH520562A patent/CH423768A/en unknown
- 1962-05-01 DK DK557963A patent/DK108168C/en active
- 1962-05-01 DK DK197762A patent/DK114342B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK108168C (en) | 1967-10-02 |
CH423768A (en) | 1966-11-15 |
ES277085A1 (en) | 1963-01-01 |
DE1468211B1 (en) | 1970-04-23 |
BE617105A (en) | 1962-10-30 |
DK114342B (en) | 1969-06-23 |
SE309590B (en) | 1969-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3704295A (en) | Steroido(3,2-c)pyrazoles and preparation thereof | |
NO122591B (en) | ||
US3317520A (en) | Steroido[20, 21-c]pyrazoles and intermediates | |
US3129218A (en) | 2-alkoxymethylene steroids of the androstane and pregnane series | |
NO132201B (en) | ||
US3290293A (en) | 4-androsteno-[3, 2-c] pyrazoles | |
SU497774A3 (en) | Method for preparing benzodiazepine derivatives | |
US2937168A (en) | 3-oxygenated androstena [16, 17-c]-3'-methylpyrazoles and derivatives | |
NO780867L (en) | PROCEDURES FOR THE PREPARATION OF STEROID-SPIRO-OXAZOLIDION DERIVATIVES | |
US3123623A (en) | Nhcochs | |
US3092623A (en) | [3, 2-c] pyrazolo-4, 9-androstadienes | |
US3148183A (en) | Delta4 and delta4, 6-17alpha-acyloxy-20-oxo-steroid-[3, 2-c] pyrazoles of the pregnane series | |
US3094521A (en) | Alkanoylthio and pyrazolo androstane derivatives | |
US3743660A (en) | 17-sulfo-acetates of estradiol | |
US3299054A (en) | 4-pregneno-[3, 2-c] pyrazoles and processes of preparing them | |
US2753341A (en) | 17-pyridineacrylyl-5-androsten-3-ols and their esters | |
US2891076A (en) | 11alpha, 12beta-dimethyl-delta4, 8(14), 13(17)-pregnatriene-3, 20-dione | |
DE1668690C3 (en) | Process for the preparation of N-substituted 4-aminosteroids of the androstane-pregnane and cholestane series | |
US3002984A (en) | Process for the preparation of 11-hydroxy-steroids | |
SU430552A1 (en) | Method for producing benzodiazepine derivatives | |
US3330824A (en) | 3-lower alkoxy estra-1, 3, 5(10) triene-[17, 16-c]-pyrazoles | |
NO115111B (en) | ||
US3088944A (en) | Pyrazole derivatives in the pregnane series | |
US3634419A (en) | 17-azasteroids | |
CH514567A (en) | 7 3 2-c-pyrazolo-pregnanes |